Isobutyric Acid Promotes Immune Evasion in Colorectal Cancer via Increased <scp>PD</scp> ‐ <scp>L1</scp> Expression
Our study elucidates a novel mechanism by which IBA inhibits the sensitivity of CRC to anti-PD-L1 antibody therapy. Emphasizing IBA and its downstream pathways as potential therapeutic targets for immune therapy resistance mechanisms, our findings provide a novel theoretical foundation for overcoming immune therapy resistance.
Authors
- Tao Luo (ORCID: https://orcid.org/0000-0002-7706-5131)
- Weizhong Tang (ORCID: https://orcid.org/0000-0003-0877-8557)
- Lin Qiu-hua
- Ying Deng (ORCID: https://orcid.org/0000-0003-1742-1197)
- Xianwei Mo (ORCID: https://orcid.org/0000-0002-4245-2836)
- Xinjie Wei (ORCID: https://orcid.org/0000-0003-1437-1569)
- Hao Lai
- Wenbo Chen (ORCID: https://orcid.org/0000-0002-4590-6741)
- Jinglian Chen
- Chunyin Wei
- Han Wang (ORCID: https://orcid.org/0009-0008-1462-649X)
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/cam4.70397
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85